Medipharm Labs Corp T.LABS

Monograph

[subaru1]

will it ever come, the waiting is getting very long.....

[subaru1i]

I know, waiting is not my favorite thing to do either.   Personally, I am thinking this month or September at the very latest since the first FDA onsite at Barrie was Sept 2022 and by the very fact of waiting for the drug monograph also means that the FDA has reviewed and approved it and the last step in their process is to issue the drug monograph.    Subaru1, call the FDA

[mdjbrown]

LOL s1   -  waiting very long in the pharma world is years, not months.  If a generic Epidiolex is in fact what is being targeted by Medipharm's global partner, Jazz is going to do everything in their power to throw a stick in those wheels of progress, and they are no strangers to using the courts as that stick when they feel threatened. Billions of dollars are a stake if

[subaru1i]

JAZZ cannot do anything legally against anyone until a product is $commercialized$ and generating revenues.  You can basically do anything you want, even if covered by a plethora of patents, the trigger point for legal action comes when you commercialize it, by definition, making money.  A patent holder then can require you to 'license' and pay royalties.    So imho

[mdjbrown]

s1i, I found this interesting as an avenue to stall competitors from advancing generic versions. One of the other contributors hear mentioned this a while back. "If a brand company sues a competitor for infringement of an Orange Book listed patent, it triggers an automatic statutorily imposed bar on the FDA’s ability to approve the competitor’s drug for up to 30 months. When triggered by an

[subaru1i]

Hmmm....after reading your post on the 30 month stay I am still wondering why Pidduck said we have a plan to generate cash in the near term.   In light of their real estate sale and Hexo settlement, I ask myself...what's that all about? 

[mdjbrown]

s1i, it could be that the folks at Medipharm are expecting big things out of their Brazilian relationships. In July 2023, the Company entered into an additional supply agreement with a top tier generic pharmaceutical company in Brazil. Under the agreement, the customer will apply to the Brazilian Health Regulatory Agency for a number of cannabis product approvals. MediPharm has

[subaru1i]

No doubt, LABS is signing up customers, be it Germany, South America, Canada or the U.S.  All those customers have one thing in common....buying cannabinoid pharmaceutical grade API's.    Add to that all of the clincal trials they have in their pipeline.     What does their global pharmaceutical 'partner' do in a case like that?  Stand by and watch

[Danno13]

I agree Subaru! Something big is just around the corner.Looking at the chart Volume has picked up.

[subaru1i]

Comment made from last CC, we invested millions in our business.    2 take aways from that for me.   1) When any growing company enters their hyper growth phase, where things really start to take off, it is usually a period where the company is burning through a lot of cash to support that hypergrowth phase.   Making that comment at the most recent CC caught my